ID   IF16_HUMAN              Reviewed;         785 AA.
AC   Q16666; A0A346JEQ3; B4DJT8; H3BLV7; Q59GX0; Q5T3W7; Q5T3W8; Q5T3X0; Q5T3X1;
AC   Q5T3X2; Q8N9E5; Q8NEQ7; Q96AJ5; Q9UH78;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   28-NOV-2006, sequence version 3.
DT   18-JUN-2025, entry version 234.
DE   RecName: Full=Gamma-interferon-inducible protein 16 {ECO:0000303|PubMed:1526658};
DE            Short=Ifi-16 {ECO:0000303|PubMed:1526658};
DE   AltName: Full=Interferon-inducible myeloid differentiation transcriptional activator;
GN   Name=IFI16 {ECO:0000303|PubMed:1526658, ECO:0000312|HGNC:HGNC:5395};
GN   Synonyms=IFNGIP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT HIS-103.
RC   TISSUE=T-cell;
RX   PubMed=1526658; DOI=10.1007/bf00218044;
RA   Trapani J.A., Browne K.A., Dawson M.J., Ramsay R.G., Eddy R.L., Show T.B.,
RA   White P.C., Dupont B.;
RT   "A novel gene constitutively expressed in human lymphoid cells is inducible
RT   with interferon-gamma in myeloid cells.";
RL   Immunogenetics 36:369-376(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2), AND VARIANT HIS-103.
RX   PubMed=7959953; DOI=10.1007/bf00177824;
RA   Trapani J.A., Dawson M.J., Apostolidis V.A., Browne K.A.;
RT   "Genomic organization of IFI16, an interferon-inducible gene whose
RT   expression is associated with human myeloid cell differentiation:
RT   correlation of predicted protein domains with exon organization.";
RL   Immunogenetics 40:415-424(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM IFI16-BETA), FUNCTION (ISOFORM
RP   IFI16-BETA), SUBCELLULAR LOCATION (ISOFORM IFI16-BETA), INTERACTION WITH
RP   STING1 AND AIM2 (ISOFORM IFI16-BETA), TISSUE SPECIFICITY (ISOFORM
RP   IFI16-BETA), AND INDUCTION (ISOFORM IFI16-BETA).
RX   PubMed=30104205; DOI=10.15252/embr.201845737;
RA   Wang P.H., Ye Z.W., Deng J.J., Siu K.L., Gao W.W., Chaudhary V., Cheng Y.,
RA   Fung S.Y., Yuen K.S., Ho T.H., Chan C.P., Zhang Y., Kok K.H., Yang W.,
RA   Chan C.P., Jin D.Y.;
RT   "Inhibition of AIM2 inflammasome activation by a novel transcript isoform
RT   of IFI16.";
RL   EMBO Rep. 19:0-0(2018).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT HIS-103.
RC   TISSUE=Bone marrow;
RA   Jiang C., Zhang D., Peng Y., Zhang X., Han Z., Fu G., Chen Z.;
RL   Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, TISSUE SPECIFICITY,
RP   INDUCTION, AND VARIANTS THR-179; SER-409 AND ASN-413.
RX   PubMed=12894224; DOI=10.1038/sj.onc.1206754;
RA   Xin H., Curry J., Johnstone R.W., Nickoloff B.J., Choubey D.;
RT   "Role of IFI 16, a member of the interferon-inducible p200-protein family,
RT   in prostate epithelial cellular senescence.";
RL   Oncogene 22:4831-4840(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), AND VARIANTS THR-179;
RP   SER-409 AND ASN-413.
RC   TISSUE=Hippocampus, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS SER-409
RP   AND ASN-413.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS THR-179;
RP   SER-409 AND ASN-413.
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   ALTERNATIVE SPLICING, SUBUNIT, PHOSPHORYLATION, AND GLYCOSYLATION.
RX   PubMed=9718316; DOI=10.1021/bi981069a;
RA   Johnstone R.W., Kershaw M.H., Trapani J.A.;
RT   "Isotypic variants of the interferon-inducible transcriptional repressor
RT   IFI 16 arise through differential mRNA splicing.";
RL   Biochemistry 37:11924-11931(1998).
RN   [11]
RP   INDUCTION, SUBCELLULAR LOCATION, AND DNA-BINDING.
RX   PubMed=7536752; DOI=10.1002/jcb.240570106;
RA   Dawson M.J., Trapani J.A.;
RT   "IFI 16 gene encodes a nuclear protein whose expression is induced by
RT   interferons in human myeloid leukaemia cell lines.";
RL   J. Cell. Biochem. 57:39-51(1995).
RN   [12]
RP   TISSUE-SPECIFIC INDUCTION.
RX   PubMed=7806273; DOI=10.1007/bf00188431;
RA   Dawson M.J., Trapani J.A., Briggs R.C., Nicholl J.K., Sutherland G.R.,
RA   Baker E.;
RT   "The closely linked genes encoding the myeloid nuclear differentiation
RT   antigen (MNDA) and IFI16 exhibit contrasting haemopoietic expression.";
RL   Immunogenetics 41:40-43(1995).
RN   [13]
RP   TISSUE SPECIFIC INDUCTION.
RX   PubMed=9766636; DOI=10.1002/jlb.64.4.546;
RA   Dawson M.J., Elwood N.J., Johnstone R.W., Trapani J.A.;
RT   "The IFN-inducible nucleoprotein IFI 16 is expressed in cells of the
RT   monocyte lineage, but is rapidly and markedly down-regulated in other
RT   myeloid precursor populations.";
RL   J. Leukoc. Biol. 64:546-554(1998).
RN   [14]
RP   FUNCTION.
RX   PubMed=9642285; DOI=10.1074/jbc.273.27.17172;
RA   Johnstone R.W., Kerry J.A., Trapani J.A.;
RT   "The human interferon-inducible protein, IFI 16, is a repressor of
RT   transcription.";
RL   J. Biol. Chem. 273:17172-17177(1998).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH TP53.
RX   PubMed=11146555; DOI=10.1038/sj.onc.1204005;
RA   Johnstone R.W., Wei W., Greenway A., Trapani J.A.;
RT   "Functional interaction between p53 and the interferon-inducible
RT   nucleoprotein IFI 16.";
RL   Oncogene 19:6033-6042(2000).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH BRCA1.
RX   PubMed=14654789; DOI=10.1038/sj.onc.1207057;
RA   Aglipay J.A., Lee S.W., Okada S., Fujiuchi N., Ohtsuka T., Kwak J.C.,
RA   Wang Y., Johnstone R.W., Deng C., Qin J., Ouchi T.;
RT   "A member of the Pyrin family, IFI16, is a novel BRCA1-associated protein
RT   involved in the p53-mediated apoptosis pathway.";
RL   Oncogene 22:8931-8938(2003).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-106, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-106 AND SER-153, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-106 AND SER-153, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-214, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [22]
RP   SUMOYLATION AT LYS-561.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20388717; DOI=10.1074/jbc.m110.106955;
RA   Blomster H.A., Imanishi S.Y., Siimes J., Kastu J., Morrice N.A.,
RA   Eriksson J.E., Sistonen L.;
RT   "In vivo identification of sumoylation sites by a signature tag and
RT   cysteine-targeted affinity purification.";
RL   J. Biol. Chem. 285:19324-19329(2010).
RN   [23]
RP   FUNCTION, DNA-BINDING, INTERACTION WITH TMEM173, AND INDUCTION.
RX   PubMed=20890285; DOI=10.1038/ni.1932;
RA   Unterholzner L., Keating S.E., Baran M., Horan K.A., Jensen S.B.,
RA   Sharma S., Sirois C.M., Jin T., Latz E., Xiao T.S., Fitzgerald K.A.,
RA   Paludan S.R., Bowie A.G.;
RT   "IFI16 is an innate immune sensor for intracellular DNA.";
RL   Nat. Immunol. 11:997-1004(2010).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-106; SER-153 AND SER-575, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [26]
RP   FUNCTION, AND INTERACTION WITH PYCARD AND CASP1.
RX   PubMed=21575908; DOI=10.1016/j.chom.2011.04.008;
RA   Kerur N., Veettil M.V., Sharma-Walia N., Bottero V., Sadagopan S.,
RA   Otageri P., Chandran B.;
RT   "IFI16 acts as a nuclear pathogen sensor to induce the inflammasome in
RT   response to Kaposi Sarcoma-associated herpesvirus infection.";
RL   Cell Host Microbe 9:363-375(2011).
RN   [27]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=21573174; DOI=10.1371/journal.pone.0019532;
RA   Duan X., Ponomareva L., Veeranki S., Choubey D.;
RT   "IFI16 induction by glucose restriction in human fibroblasts contributes to
RT   autophagy through activation of the ATM/AMPK/p53 pathway.";
RL   PLoS ONE 6:E19532-E19532(2011).
RN   [28]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH AIM2.
RX   PubMed=22046441; DOI=10.1371/journal.pone.0027040;
RA   Veeranki S., Duan X., Panchanathan R., Liu H., Choubey D.;
RT   "IFI16 protein mediates the anti-inflammatory actions of the type-I
RT   interferons through suppression of activation of caspase-1 by
RT   inflammasomes.";
RL   PLoS ONE 6:E27040-E27040(2011).
RN   [29]
RP   DNA-BINDING.
RX   PubMed=22618232; DOI=10.1016/j.bbrc.2012.05.065;
RA   Brazda V., Coufal J., Liao J.C., Arrowsmith C.H.;
RT   "Preferential binding of IFI16 protein to cruciform structure and
RT   superhelical DNA.";
RL   Biochem. Biophys. Res. Commun. 422:716-720(2012).
RN   [30]
RP   FUNCTION, AND INTERACTION WITH SP1.
RX   PubMed=22291595; DOI=10.1371/journal.ppat.1002498;
RA   Gariano G.R., Dell'Oste V., Bronzini M., Gatti D., Luganini A.,
RA   De Andrea M., Gribaudo G., Gariglio M., Landolfo S.;
RT   "The intracellular DNA sensor IFI16 gene acts as restriction factor for
RT   human cytomegalovirus replication.";
RL   PLoS Pathog. 8:E1002498-E1002498(2012).
RN   [31]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PROTEASOMAL DEGRADATION.
RX   PubMed=23027953; DOI=10.1073/pnas.1211302109;
RA   Orzalli M.H., DeLuca N.A., Knipe D.M.;
RT   "Nuclear IFI16 induction of IRF-3 signaling during herpesviral infection
RT   and degradation of IFI16 by the viral ICP0 protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:E3008-E3017(2012).
RN   [32]
RP   SUBCELLULAR LOCATION, IDENTIFICATION BY MASS SPECTROMETRY, PHOSPHORYLATION
RP   AT SER-95; SER-106; SER-153; SER-168; SER-174 AND SER-780, ACETYLATION AT
RP   LYS-45; LYS-99; LYS-128; LYS-214; LYS-444; LYS-451; LYS-561; LYS-598 AND
RP   LYS-614, AND MUTAGENESIS OF 96-ARG--LYS-100; LYS-99; LYS-128;
RP   128-LYS--LYS-131; 134-LYS--LYS-136 AND 140-LYS--LYS-143.
RX   PubMed=22691496; DOI=10.1073/pnas.1203447109;
RA   Li T., Diner B.A., Chen J., Cristea I.M.;
RT   "Acetylation modulates cellular distribution and DNA sensing ability of
RT   interferon-inducible protein IFI16.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:10558-10563(2012).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-106 AND SER-153, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [34]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=24198334; DOI=10.1073/pnas.1316194110;
RA   Orzalli M.H., Conwell S.E., Berrios C., DeCaprio J.A., Knipe D.M.;
RT   "Nuclear interferon-inducible protein 16 promotes silencing of herpesviral
RT   and transfected DNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:E4492-E4501(2013).
RN   [35]
RP   FUNCTION, INTERACTION WITH MTA1, AND SUBCELLULAR LOCATION.
RX   PubMed=24413532; DOI=10.1158/0008-5472.can-13-2020;
RA   Kang H.J., Lee M.H., Kang H.L., Kim S.H., Ahn J.R., Na H., Na T.Y.,
RA   Kim Y.N., Seong J.K., Lee M.O.;
RT   "Differential regulation of estrogen receptor alpha expression in breast
RT   cancer cells by metastasis-associated protein 1.";
RL   Cancer Res. 74:1484-1494(2014).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-106 AND SER-153, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [37]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PYDC5.
RX   PubMed=24531343; DOI=10.1038/ni.2829;
RA   Khare S., Ratsimandresy R.A., de Almeida L., Cuda C.M., Rellick S.L.,
RA   Misharin A.V., Wallin M.C., Gangopadhyay A., Forte E., Gottwein E.,
RA   Perlman H., Reed J.C., Greaves D.R., Dorfleutner A., Stehlik C.;
RT   "The PYRIN domain-only protein POP3 inhibits ALR inflammasomes and
RT   regulates responses to infection with DNA viruses.";
RL   Nat. Immunol. 15:343-353(2014).
RN   [38]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-116 AND LYS-561, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [39]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-561, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [40]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-561 AND LYS-683, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [41]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-116; LYS-128; LYS-561 AND
RP   LYS-683, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 192-393, AND MUTAGENESIS OF
RP   TYR-218; GLU-222; TYR-267 AND GLU-272.
RX   PubMed=21397192; DOI=10.1016/j.str.2010.12.015;
RA   Liao J.C., Lam R., Brazda V., Duan S., Ravichandran M., Ma J., Xiao T.,
RA   Tempel W., Zuo X., Wang Y.X., Chirgadze N.Y., Arrowsmith C.H.;
RT   "Interferon-inducible protein 16: insight into the interaction with tumor
RT   suppressor p53.";
RL   Structure 19:418-429(2011).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 571-766 IN COMPLEX WITH
RP   DOUBLE-STRANDED DNA, AND MUTAGENESIS OF LYS-627; LYS-663; ARG-667; SER-670;
RP   LYS-674; LYS-732; LYS-734 AND LYS-759.
RX   PubMed=22483801; DOI=10.1016/j.immuni.2012.02.014;
RA   Jin T., Perry A., Jiang J., Smith P., Curry J.A., Unterholzner L.,
RA   Jiang Z., Horvath G., Rathinam V.A., Johnstone R.W., Hornung V., Latz E.,
RA   Bowie A.G., Fitzgerald K.A., Xiao T.S.;
RT   "Structures of the HIN domain:DNA complexes reveal ligand binding and
RT   activation mechanisms of the AIM2 inflammasome and IFI16 receptor.";
RL   Immunity 36:561-571(2012).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 192-393.
RG   Northeast structural genomics consortium (NESG);
RT   "Crystal structure of the first HIN-200 domain of interferon-inducible
RT   protein 16.";
RL   Submitted (FEB-2007) to the PDB data bank.
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 571-766.
RG   Northeast structural genomics consortium (NESG);
RT   "Crystal structure analysis of the second HIN domain of IFI16.";
RL   Submitted (NOV-2007) to the PDB data bank.
CC   -!- FUNCTION: Binds double-stranded DNA. Binds preferentially to
CC       supercoiled DNA and cruciform DNA structures. Seems to be involved in
CC       transcriptional regulation. May function as a transcriptional
CC       repressor. Could have a role in the regulation of hematopoietic
CC       differentiation through activation of unknown target genes. Controls
CC       cellular proliferation by modulating the functions of cell cycle
CC       regulatory factors including p53/TP53 and the retinoblastoma protein.
CC       May be involved in TP53-mediated transcriptional activation by
CC       enhancing TP53 sequence-specific DNA binding and modulating TP53
CC       phosphorylation status. Seems to be involved in energy-level-dependent
CC       activation of the ATM/ AMPK/TP53 pathway coupled to regulation of
CC       autophagy. May be involved in regulation of TP53-mediated cell death
CC       also involving BRCA1. May be involved in the senescence of prostate
CC       epithelial cells. Involved in innate immune response by recognizing
CC       viral dsDNA in the cytosol and probably in the nucleus. After binding
CC       to viral DNA in the cytoplasm recruits TMEM173/STING and mediates the
CC       induction of IFN-beta. Has anti-inflammatory activity and inhibits the
CC       activation of the AIM2 inflammasome, probably via association with
CC       AIM2. Proposed to bind viral DNA in the nucleus, such as of Kaposi's
CC       sarcoma-associated herpesvirus, and to induce the formation of nuclear
CC       caspase-1-activating inflammasome formation via association with
CC       PYCARD. Inhibits replication of herpesviruses such as human
CC       cytomegalovirus (HCMV) probably by interfering with promoter
CC       recruitment of members of the Sp1 family of transcription factors.
CC       Necessary to activate the IRF3 signaling cascade during human herpes
CC       simplex virus 1 (HHV-1) infection and promotes the assembly of
CC       heterochromatin on herpesviral DNA and inhibition of viral immediate-
CC       early gene expression and replication. Involved in the MTA1-mediated
CC       epigenetic regulation of ESR1 expression in breast cancer.
CC       {ECO:0000269|PubMed:11146555, ECO:0000269|PubMed:12894224,
CC       ECO:0000269|PubMed:14654789, ECO:0000269|PubMed:20890285,
CC       ECO:0000269|PubMed:21573174, ECO:0000269|PubMed:21575908,
CC       ECO:0000269|PubMed:22046441, ECO:0000269|PubMed:22291595,
CC       ECO:0000269|PubMed:23027953, ECO:0000269|PubMed:24198334,
CC       ECO:0000269|PubMed:24413532, ECO:0000269|PubMed:9642285}.
CC   -!- FUNCTION: [Isoform IFI16-beta]: Isoform that specifically inhibits the
CC       AIM2 inflammasome (PubMed:30104205). Binds double-stranded DNA (dsDNA)
CC       in the cytoplasm, impeding its detection by AIM2 (PubMed:30104205).
CC       Also prevents the interaction between AIM2 and PYCARD/ASC via its
CC       interaction with AIM2, thereby inhibiting assembly of the AIM2
CC       inflammasome (PubMed:30104205). This isoform also weakly induce
CC       production of type I interferon-beta (IFNB1) via its interaction with
CC       STING1 (PubMed:30104205). {ECO:0000269|PubMed:30104205}.
CC   -!- SUBUNIT: Forms homooligomers; isoform 2 can self-associate or associate
CC       with isoform 1 or isoform 3. Interacts with TMEM173, AIM2, PYCARD and
CC       CASP1. Interacts with BRCA1, TP53, E2F1, RB1 and SP1. Interacts with
CC       MTA1. Interacts with PYDC5 (PubMed:24531343).
CC       {ECO:0000269|PubMed:11146555, ECO:0000269|PubMed:14654789,
CC       ECO:0000269|PubMed:20890285, ECO:0000269|PubMed:21575908,
CC       ECO:0000269|PubMed:22046441, ECO:0000269|PubMed:22291595,
CC       ECO:0000269|PubMed:22483801, ECO:0000269|PubMed:24413532,
CC       ECO:0000269|PubMed:24531343, ECO:0000269|PubMed:9718316}.
CC   -!- SUBUNIT: [Isoform IFI16-beta]: Interacts with AIM2; preventing the
CC       interaction between AIM2 and PYCARD/ASC (PubMed:30104205). Interacts
CC       with STING1 (PubMed:30104205). {ECO:0000269|PubMed:30104205}.
CC   -!- INTERACTION:
CC       Q16666; P10275: AR; NbExp=3; IntAct=EBI-2867186, EBI-608057;
CC       Q16666; P38398: BRCA1; NbExp=9; IntAct=EBI-2867186, EBI-349905;
CC       Q16666; Q96C10: DHX58; NbExp=2; IntAct=EBI-2867186, EBI-744193;
CC       Q16666; Q86WV6: STING1; NbExp=2; IntAct=EBI-2867186, EBI-2800345;
CC       Q16666-2; Q16666-2: IFI16; NbExp=3; IntAct=EBI-6273540, EBI-6273540;
CC       Q16666-2; P04637: TP53; NbExp=6; IntAct=EBI-6273540, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:24413532,
CC       ECO:0000269|PubMed:24531343, ECO:0000269|PubMed:7536752}. Cytoplasm
CC       {ECO:0000269|PubMed:22691496}. Note=Cellular distribution is dependent
CC       on the acetylation status of the multipartite nuclear localization
CC       signal (NLS); NLS acetylation promotes cytoplasmic localization.
CC       Localizes in the nucleus during human herpes simplex virus 1 (HHV-1)
CC       infection. {ECO:0000269|PubMed:22691496}.
CC   -!- SUBCELLULAR LOCATION: [Isoform IFI16-beta]: Cytoplasm
CC       {ECO:0000269|PubMed:30104205}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=IFI 16A;
CC         IsoId=Q16666-1; Sequence=Displayed;
CC       Name=2; Synonyms=IFI 16B;
CC         IsoId=Q16666-2; Sequence=VSP_002676;
CC       Name=3; Synonyms=IFI 16C;
CC         IsoId=Q16666-3; Sequence=VSP_002675;
CC       Name=4;
CC         IsoId=Q16666-6; Sequence=VSP_044691;
CC       Name=IFI16-beta;
CC         IsoId=Q16666-8; Sequence=VSP_061846, VSP_061847;
CC   -!- TISSUE SPECIFICITY: Expressed in peripheral blood leukocytes,
CC       fibroblasts and lymphoid cells. Present in myeloid precursors (CD34+)
CC       and throughout monocyte development, but its expression is down-
CC       regulated in erythroid and polymorphonuclear precursor cells. Present
CC       in prostate, ovary and breast (at protein level).
CC       {ECO:0000269|PubMed:12894224}.
CC   -!- TISSUE SPECIFICITY: [Isoform IFI16-beta]: Widely expressed.
CC       {ECO:0000269|PubMed:30104205}.
CC   -!- INDUCTION: Strongly induced by IFNG/IFN-gamma and, to a lesser extent,
CC       by alpha interferon. In HL-60 cells, maximum induction by IFNG/IFN-
CC       gamma occurs within 12 hours whereas, for IFN-alpha, only 10-fold
CC       induction was observed after 36 hours. Induced in vitro by
CC       dimethylsulfoxide, retinoic acid and 1,25 dihydroxyvitamin D3. Induced
CC       in monocytes by IFN-alpha and viral dsDNA. Induced by glucose
CC       restriction. {ECO:0000269|PubMed:12894224, ECO:0000269|PubMed:20890285,
CC       ECO:0000269|PubMed:21573174, ECO:0000269|PubMed:7536752}.
CC   -!- INDUCTION: [Isoform IFI16-beta]: By interferon-beta (IFNB1).
CC       {ECO:0000269|PubMed:30104205}.
CC   -!- DOMAIN: The HIN-200 domains mediates dsDNA binding via electrostatic
CC       interactions. {ECO:0000269|PubMed:22483801}.
CC   -!- PTM: Ubiquitinated by human herpes simplex virus 1 (HHV-1) ICP0
CC       protein; leading to degradation by the proteasome.
CC   -!- PTM: Lysine acetylation in the multipartite nuclear localization signal
CC       (NLS) regulates the subcellular location. In vitro can be acetylated by
CC       p300/EP300 coupled to cytoplasmic localization.
CC       {ECO:0000269|PubMed:22691496}.
CC   -!- PTM: Phosphorylated on Ser and Thr. {ECO:0000269|PubMed:22691496,
CC       ECO:0000269|PubMed:9718316}.
CC   -!- PTM: Isoform 3 seems to show a minor degree of complex carbohydrate
CC       addition.
CC   -!- MISCELLANEOUS: [Isoform 2]: Major isoform. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the HIN-200 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF20997.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAF20997.1; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305};
CC       Sequence=BAC04462.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};
CC       Sequence=BAD92226.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAG58950.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M63838; AAA58683.1; -; mRNA.
DR   EMBL; S75433; AAB32519.2; -; Genomic_DNA.
DR   EMBL; S75417; AAB32519.2; JOINED; Genomic_DNA.
DR   EMBL; S75419; AAB32519.2; JOINED; Genomic_DNA.
DR   EMBL; S75421; AAB32519.2; JOINED; Genomic_DNA.
DR   EMBL; S75423; AAB32519.2; JOINED; Genomic_DNA.
DR   EMBL; S75424; AAB32519.2; JOINED; Genomic_DNA.
DR   EMBL; S75426; AAB32519.2; JOINED; Genomic_DNA.
DR   EMBL; S75429; AAB32519.2; JOINED; Genomic_DNA.
DR   EMBL; S75431; AAB32519.2; JOINED; Genomic_DNA.
DR   EMBL; MH445452; AXP31978.1; -; mRNA.
DR   EMBL; AF208043; AAF20997.1; ALT_SEQ; mRNA.
DR   EMBL; AY138863; AAM96005.1; -; mRNA.
DR   EMBL; AK094968; BAC04462.1; ALT_SEQ; mRNA.
DR   EMBL; AK296228; BAG58950.1; ALT_INIT; mRNA.
DR   EMBL; AB208989; BAD92226.1; ALT_INIT; mRNA.
DR   EMBL; AL359753; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC017059; AAH17059.1; -; mRNA.
DR   CCDS; CCDS1180.3; -. [Q16666-2]
DR   CCDS; CCDS58039.1; -. [Q16666-6]
DR   CCDS; CCDS91079.1; -. [Q16666-1]
DR   CCDS; CCDS91080.1; -. [Q16666-3]
DR   PIR; I54501; I54501.
DR   RefSeq; NP_001193496.1; NM_001206567.2. [Q16666-6]
DR   RefSeq; NP_001351796.1; NM_001364867.2. [Q16666-1]
DR   RefSeq; NP_001363516.1; NM_001376587.1. [Q16666-1]
DR   RefSeq; NP_001363517.1; NM_001376588.1. [Q16666-2]
DR   RefSeq; NP_001363518.1; NM_001376589.1. [Q16666-2]
DR   RefSeq; NP_001363520.1; NM_001376591.1. [Q16666-3]
DR   RefSeq; NP_001363521.1; NM_001376592.1. [Q16666-3]
DR   RefSeq; NP_005522.2; NM_005531.3. [Q16666-2]
DR   PDB; 2OQ0; X-ray; 2.00 A; A/B/C/D=192-393.
DR   PDB; 3B6Y; X-ray; 2.35 A; A/B=571-766.
DR   PDB; 3RLN; X-ray; 2.25 A; A=571-766.
DR   PDB; 3RLO; X-ray; 1.80 A; A=571-766.
DR   PDB; 3RNU; X-ray; 2.50 A; A/B/C/D=571-766.
DR   PDB; 4QGU; X-ray; 2.54 A; A/B=192-393.
DR   PDB; 8X70; X-ray; 1.70 A; A/B/C/D=192-393.
DR   PDBsum; 2OQ0; -.
DR   PDBsum; 3B6Y; -.
DR   PDBsum; 3RLN; -.
DR   PDBsum; 3RLO; -.
DR   PDBsum; 3RNU; -.
DR   PDBsum; 4QGU; -.
DR   PDBsum; 8X70; -.
DR   AlphaFoldDB; Q16666; -.
DR   SMR; Q16666; -.
DR   BioGRID; 109654; 758.
DR   CORUM; Q16666; -.
DR   DIP; DIP-42868N; -.
DR   FunCoup; Q16666; 542.
DR   IntAct; Q16666; 192.
DR   MINT; Q16666; -.
DR   STRING; 9606.ENSP00000357113; -.
DR   CarbonylDB; Q16666; -.
DR   GlyConnect; 1263; 1 N-Linked glycan (1 site).
DR   GlyCosmos; Q16666; 1 site, 1 glycan.
DR   GlyGen; Q16666; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site).
DR   iPTMnet; Q16666; -.
DR   MetOSite; Q16666; -.
DR   PhosphoSitePlus; Q16666; -.
DR   SwissPalm; Q16666; -.
DR   BioMuta; IFI16; -.
DR   DMDM; 118572657; -.
DR   jPOST; Q16666; -.
DR   MassIVE; Q16666; -.
DR   PaxDb; 9606-ENSP00000357113; -.
DR   PeptideAtlas; Q16666; -.
DR   ProteomicsDB; 40733; -.
DR   ProteomicsDB; 61023; -. [Q16666-1]
DR   ProteomicsDB; 61024; -. [Q16666-2]
DR   ProteomicsDB; 61025; -. [Q16666-3]
DR   Pumba; Q16666; -.
DR   Antibodypedia; 988; 358 antibodies from 34 providers.
DR   DNASU; 3428; -.
DR   Ensembl; ENST00000295809.12; ENSP00000295809.7; ENSG00000163565.20. [Q16666-1]
DR   Ensembl; ENST00000359709.7; ENSP00000352740.3; ENSG00000163565.20. [Q16666-6]
DR   Ensembl; ENST00000368131.8; ENSP00000357113.4; ENSG00000163565.20. [Q16666-2]
DR   Ensembl; ENST00000368132.7; ENSP00000357114.3; ENSG00000163565.20. [Q16666-2]
DR   Ensembl; ENST00000448393.6; ENSP00000404325.2; ENSG00000163565.20. [Q16666-3]
DR   GeneID; 3428; -.
DR   KEGG; hsa:3428; -.
DR   MANE-Select; ENST00000295809.12; ENSP00000295809.7; NM_001376587.1; NP_001363516.1.
DR   UCSC; uc001ftg.4; human. [Q16666-1]
DR   AGR; HGNC:5395; -.
DR   CTD; 3428; -.
DR   DisGeNET; 3428; -.
DR   GeneCards; IFI16; -.
DR   HGNC; HGNC:5395; IFI16.
DR   HPA; ENSG00000163565; Low tissue specificity.
DR   MIM; 147586; gene.
DR   OpenTargets; ENSG00000163565; -.
DR   VEuPathDB; HostDB:ENSG00000163565; -.
DR   eggNOG; ENOG502QTQS; Eukaryota.
DR   GeneTree; ENSGT00390000013296; -.
DR   HOGENOM; CLU_022874_0_0_1; -.
DR   InParanoid; Q16666; -.
DR   OMA; FIYYEIR; -.
DR   OrthoDB; 9622064at2759; -.
DR   PAN-GO; Q16666; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; Q16666; -.
DR   PathwayCommons; Q16666; -.
DR   Reactome; R-HSA-1834941; STING mediated induction of host immune responses.
DR   Reactome; R-HSA-3270619; IRF3-mediated induction of type I IFN.
DR   SignaLink; Q16666; -.
DR   SIGNOR; Q16666; -.
DR   BioGRID-ORCS; 3428; 16 hits in 1166 CRISPR screens.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   ChiTaRS; IFI16; human.
DR   EvolutionaryTrace; Q16666; -.
DR   GeneWiki; IFI16; -.
DR   GenomeRNAi; 3428; -.
DR   Pharos; Q16666; Tbio.
DR   PRO; PR:Q16666; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q16666; protein.
DR   Bgee; ENSG00000163565; Expressed in germinal epithelium of ovary and 218 other cell types or tissues.
DR   ExpressionAtlas; Q16666; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IDA:MGI.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003690; F:double-stranded DNA binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IDA:UniProtKB.
DR   GO; GO:0002218; P:activation of innate immune response; IBA:GO_Central.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB.
DR   GO; GO:0035458; P:cellular response to interferon-beta; IBA:GO_Central.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IDA:UniProtKB.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IMP:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:MGI.
DR   GO; GO:0030224; P:monocyte differentiation; IDA:UniProtKB.
DR   GO; GO:0030099; P:myeloid cell differentiation; NAS:UniProtKB.
DR   GO; GO:0140972; P:negative regulation of AIM2 inflammasome complex assembly; IDA:UniProtKB.
DR   GO; GO:0043392; P:negative regulation of DNA binding; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0045814; P:negative regulation of gene expression, epigenetic; IMP:UniProtKB.
DR   GO; GO:0045824; P:negative regulation of innate immune response; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; IDA:UniProtKB.
DR   GO; GO:0001819; P:positive regulation of cytokine production; TAS:UniProtKB.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0010506; P:regulation of autophagy; IEP:UniProtKB.
DR   GO; GO:0050727; P:regulation of inflammatory response; IDA:UniProtKB.
DR   CDD; cd08305; Pyrin; 1.
DR   FunFam; 1.10.533.10:FF:000011; Myeloid cell nuclear differentiation antigen; 1.
DR   FunFam; 2.40.50.140:FF:000101; Myeloid cell nuclear differentiation antigen; 2.
DR   FunFam; 2.40.50.140:FF:000105; Myeloid cell nuclear differentiation antigen; 2.
DR   Gene3D; 1.10.533.10; Death Domain, Fas; 1.
DR   Gene3D; 2.40.50.140; Nucleic acid-binding proteins; 4.
DR   IDEAL; IID00478; -.
DR   InterPro; IPR004020; DAPIN.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR040205; HIN-200.
DR   InterPro; IPR004021; HIN200/IF120x.
DR   InterPro; IPR012340; NA-bd_OB-fold.
DR   PANTHER; PTHR12200:SF5; GAMMA-INTERFERON-INDUCIBLE PROTEIN 16; 1.
DR   PANTHER; PTHR12200; INTERFERON-INDUCIBLE PROTEIN AIM2 FAMILY MEMBER; 1.
DR   Pfam; PF02760; HIN; 2.
DR   Pfam; PF02758; PYRIN; 1.
DR   SMART; SM01289; PYRIN; 1.
DR   SUPFAM; SSF159141; HIN-2000 domain-like; 4.
DR   PROSITE; PS50824; DAPIN; 1.
DR   PROSITE; PS50834; HIN_200; 2.
DR   neXtProt; NX_Q16666; -.
DR   PharmGKB; PA29642; -.
DR   TreeFam; TF337385; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing; Apoptosis;
KW   Autophagy; Cytoplasm; DNA-binding; Immunity; Inflammatory response;
KW   Innate immunity; Isopeptide bond; Nucleus; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Repeat; Repressor;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..785
FT                   /note="Gamma-interferon-inducible protein 16"
FT                   /id="PRO_0000153723"
FT   DOMAIN          1..88
FT                   /note="Pyrin"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00061"
FT   DOMAIN          189..389
FT                   /note="HIN-200 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00106"
FT   DOMAIN          562..761
FT                   /note="HIN-200 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00106"
FT   REGION          91..191
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          192..393
FT                   /note="Interaction with TP53 C-terminus"
FT   REGION          390..442
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          571..766
FT                   /note="Interaction with TP53 core domain"
FT   MOTIF           96..100
FT                   /note="Nuclear localization signal"
FT   MOTIF           128..131
FT                   /note="Nuclear localization signal"
FT   MOTIF           134..136
FT                   /note="Nuclear localization signal"
FT   MOTIF           140..143
FT                   /note="Nuclear localization signal"
FT   COMPBIAS        104..114
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        134..146
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        168..185
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         45
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MOD_RES         95
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MOD_RES         99
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MOD_RES         106
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:22691496,
FT                   ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         128
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MOD_RES         153
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:22691496,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         168
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MOD_RES         174
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MOD_RES         214
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:22691496,
FT                   ECO:0007744|PubMed:19608861"
FT   MOD_RES         444
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MOD_RES         451
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MOD_RES         561
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MOD_RES         575
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         598
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MOD_RES         614
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MOD_RES         780
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   CROSSLNK        116
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        128
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        561
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        561
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        683
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..158
FT                   /note="Missing (in isoform IFI16-beta)"
FT                   /id="VSP_061846"
FT   VAR_SEQ         128..183
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044691"
FT   VAR_SEQ         444..555
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_002675"
FT   VAR_SEQ         444..499
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:12894224,
FT                   ECO:0000303|PubMed:1526658, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|Ref.4, ECO:0000303|Ref.7"
FT                   /id="VSP_002676"
FT   VAR_SEQ         470..525
FT                   /note="Missing (in isoform IFI16-beta)"
FT                   /id="VSP_061847"
FT   VARIANT         103
FT                   /note="D -> H (in dbSNP:rs1057018)"
FT                   /evidence="ECO:0000269|PubMed:1526658,
FT                   ECO:0000269|PubMed:7959953, ECO:0000269|Ref.4"
FT                   /id="VAR_029486"
FT   VARIANT         179
FT                   /note="S -> T (in dbSNP:rs866484)"
FT                   /evidence="ECO:0000269|PubMed:12894224,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:15489334"
FT                   /id="VAR_029487"
FT   VARIANT         202
FT                   /note="K -> E (in dbSNP:rs11585341)"
FT                   /id="VAR_029488"
FT   VARIANT         409
FT                   /note="R -> S (in dbSNP:rs1057027)"
FT                   /evidence="ECO:0000269|PubMed:12894224,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|Ref.7"
FT                   /id="VAR_029489"
FT   VARIANT         413
FT                   /note="Y -> N (in dbSNP:rs1057028)"
FT                   /evidence="ECO:0000269|PubMed:12894224,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|Ref.7"
FT                   /id="VAR_029490"
FT   VARIANT         723
FT                   /note="T -> S (in dbSNP:rs6940)"
FT                   /id="VAR_029491"
FT   VARIANT         779
FT                   /note="T -> S (in dbSNP:rs6940)"
FT                   /id="VAR_057582"
FT   MUTAGEN         96..100
FT                   /note="Missing: Predominant cytoplasmic localization."
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MUTAGEN         99
FT                   /note="K->Q: Predominant cytoplasmic, reduces nuclear
FT                   localization (mimics non-acetylated state)."
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MUTAGEN         99
FT                   /note="K->R: Minor effect on nuclear localization (mimics
FT                   acetylated state)."
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MUTAGEN         128..131
FT                   /note="Missing: Predominant nuclear, some cytoplasmic
FT                   localization."
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MUTAGEN         128
FT                   /note="K->Q: Predominant cytoplasmic, reduces nuclear
FT                   localization (mimics non-acetylated state)."
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MUTAGEN         128
FT                   /note="K->R: Minor effect on nuclear localization (mimics
FT                   acetylated state)."
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MUTAGEN         134..136
FT                   /note="Missing: Mostly nuclear, minor cytoplasmic
FT                   localization."
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MUTAGEN         140..143
FT                   /note="Missing: Mostly nuclear, minor cytoplasmic
FT                   localization."
FT                   /evidence="ECO:0000269|PubMed:22691496"
FT   MUTAGEN         218
FT                   /note="Y->A: Abolishes TP53-mediated transcriptional
FT                   activation; when associated with A-267."
FT                   /evidence="ECO:0000269|PubMed:21397192"
FT   MUTAGEN         222
FT                   /note="E->A: Abolishes TP53-mediated transcriptional
FT                   activation; when associated with A-272."
FT                   /evidence="ECO:0000269|PubMed:21397192"
FT   MUTAGEN         267
FT                   /note="Y->A: Abolishes TP53-mediated transcriptional
FT                   activation; when associated with A-218."
FT                   /evidence="ECO:0000269|PubMed:21397192"
FT   MUTAGEN         272
FT                   /note="E->A: Abolishes TP53-mediated transcriptional
FT                   activation; when associated with A-222."
FT                   /evidence="ECO:0000269|PubMed:21397192"
FT   MUTAGEN         627
FT                   /note="K->A: Impairs DNA binding; when associated with
FT                   A-663; A-667; A-670; A-674; A-732; A-734 and A-759."
FT                   /evidence="ECO:0000269|PubMed:22483801"
FT   MUTAGEN         663
FT                   /note="K->A: Impairs DNA binding; when associated with
FT                   A-627; A-667; A-670; A-674; A-732; A-734 and A-759."
FT                   /evidence="ECO:0000269|PubMed:22483801"
FT   MUTAGEN         667
FT                   /note="R->A: Impairs DNA binding; when associated with
FT                   A-627; A-663; A-670; A-674; A-732; A-734 and A-759."
FT                   /evidence="ECO:0000269|PubMed:22483801"
FT   MUTAGEN         670
FT                   /note="S->A: Impairs DNA binding; when associated with
FT                   A-627; A-663; A-667; A-674; A-732; A-734 and A-759."
FT                   /evidence="ECO:0000269|PubMed:22483801"
FT   MUTAGEN         674
FT                   /note="K->A: Impairs DNA binding; when associated with
FT                   A-627; A-663; A-667; A-670; A-732; A-734 and A-759."
FT                   /evidence="ECO:0000269|PubMed:22483801"
FT   MUTAGEN         732
FT                   /note="K->A: Impairs DNA binding; when associated with
FT                   A-627; A-663; A-667; A-670; A- 674; A-734 and A-759."
FT                   /evidence="ECO:0000269|PubMed:22483801"
FT   MUTAGEN         734
FT                   /note="K->A: Impairs DNA binding; when associated with
FT                   A-627; A-663; A-667; A-670; A- 674; A-732 and A-759."
FT                   /evidence="ECO:0000269|PubMed:22483801"
FT   MUTAGEN         759
FT                   /note="K->A: Impairs DNA binding; when associated with
FT                   A-627; A-663; A-667; A-670; A- 674; A-732 and A-734."
FT                   /evidence="ECO:0000269|PubMed:22483801"
FT   CONFLICT        401
FT                   /note="S -> G (in Ref. 6; BAG58950)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        544
FT                   /note="P -> S (in Ref. 6; BAG58950)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        683
FT                   /note="K -> R (in Ref. 5; AAM96005)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        723
FT                   /note="T -> N (in Ref. 1; AAA58683 and 2; AAB32519)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        737
FT                   /note="C -> S (in Ref. 1; AAA58683 and 2; AAB32519)"
FT                   /evidence="ECO:0000305"
FT   STRAND          205..212
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   STRAND          216..219
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   STRAND          225..234
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   STRAND          239..244
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   HELIX           247..253
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   STRAND          254..257
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   STRAND          259..267
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   STRAND          270..273
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   STRAND          278..281
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   HELIX           284..286
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   HELIX           292..298
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   HELIX           304..307
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   STRAND          315..327
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   STRAND          329..338
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   STRAND          341..348
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   HELIX           349..351
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   STRAND          361..372
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   STRAND          375..379
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   STRAND          385..388
FT                   /evidence="ECO:0007829|PDB:2OQ0"
FT   STRAND          578..585
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   STRAND          589..592
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   TURN            593..596
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   STRAND          597..605
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   STRAND          610..615
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   HELIX           618..620
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   TURN            621..624
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   STRAND          629..634
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   STRAND          636..638
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   STRAND          641..644
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   STRAND          648..652
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   STRAND          655..657
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   HELIX           663..670
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   HELIX           675..679
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   STRAND          685..699
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   STRAND          702..709
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   STRAND          712..718
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   HELIX           720..724
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   STRAND          732..741
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   TURN            744..747
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   STRAND          749..761
FT                   /evidence="ECO:0007829|PDB:3RLO"
FT   TURN            764..766
FT                   /evidence="ECO:0007829|PDB:3RLO"
SQ   SEQUENCE   785 AA;  88256 MW;  216CD103D8F5206A CRC64;
     MGKKYKNIVL LKGLEVINDY HFRMVKSLLS NDLKLNLKMR EEYDKIQIAD LMEEKFRGDA
     GLGKLIKIFE DIPTLEDLAE TLKKEKLKVK GPALSRKRKK EVDATSPAPS TSSTVKTEGA
     EATPGAQKRK KSTKEKAGPK GSKVSEEQTQ PPSPAGAGMS TAMGRSPSPK TSLSAPPNSS
     STENPKTVAK CQVTPRRNVL QKRPVIVKVL STTKPFEYET PEMEKKIMFH ATVATQTQFF
     HVKVLNTSLK EKFNGKKIII ISDYLEYDSL LEVNEESTVS EAGPNQTFEV PNKIINRAKE
     TLKIDILHKQ ASGNIVYGVF MLHKKTVNQK TTIYEIQDDR GKMDVVGTGQ CHNIPCEEGD
     KLQLFCFRLR KKNQMSKLIS EMHSFIQIKK KTNPRNNDPK SMKLPQEQRQ LPYPSEASTT
     FPESHLRTPQ MPPTTPSSSF FTKKSEDTIS KMNDFMRMQI LKEGSHFPGP FMTSIGPAES
     HPHTPQMPPS TPSSSFLTTK SEDTISKMND FMRMQILKEG SHFPGPFMTS IGPAESHPHT
     PQMPPSTPSS SFLTTLKPRL KTEPEEVSIE DSAQSDLKEV MVLNATESFV YEPKEQKKMF
     HATVATENEV FRVKVFNIDL KEKFTPKKII AIANYVCRNG FLEVYPFTLV ADVNADRNME
     IPKGLIRSAS VTPKINQLCS QTKGSFVNGV FEVHKKNVRG EFTYYEIQDN TGKMEVVVHG
     RLTTINCEEG DKLKLTCFEL APKSGNTGEL RSVIHSHIKV IKTRKNKKDI LNPDSSMETS
     PDFFF
//
